Revance Announces CEO Transition
Revance announced a leadership transition last week as part of a long-term succession strategy following its integration with Crown Laboratories, according to a news release from the company.
Founder and CEO of Crown Laboratories Jeff Bedard will assume the role of Executive Chairman of the Board effective October 1, 2025, and current president, Chief Operative Officer, and Chief Financial Officer, Nadeem Moiz, will become Chief Executive Officer, according to a press release published on May 21.
The transition reflects a strategic effort to support Revance’s evolution as global leader in injectables, skin quality, and skincare solutions, the news release said. Under Bedard’s tenure, the company pointed to diverse portfolio including both consumer brands and advanced aesthetic products. As Executive Chairman, Bedard said he will continue to guide the company’s long-term vision and strategic initiatives, with a focus on partnerships and customer engagement. Moiz will oversee day-to-day operations and execution of Revance’s growth strategy, while continuing to report to Bedard.
“I founded Crown 25 years ago with a vision to develop a unique portfolio of safe and effective scientific solutions for life-long healthy skin. Alongside my talented team members, we have achieved this goal and positioned the company for our next chapter of success, with the addition and integration of Revance Therapeutics' innovative aesthetics solutions," said Bedard in the news release. "Now, as we look to the future, I am thrilled to take on the role of Executive Chairman and have Nadeem step into the CEO position to help further accelerate our growth for years to come.”
Revance notes that Moiz joined the company in 2022 and has played a key role in driving operational scale, financial efficiency, and innovation. Revance Therapeutics was acquired by Crown Laboratories in 2025. The combined entity now operates under the Revance name and includes established skincare brands such as PanOxyl, Blue Lizard, and StriVectin, alongside its aesthetics offerings.